ACTINOGEN MEDICAL LIMITED
ASX:ACWPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 89.5% of what they think they own, once every option and right converts.
Runway 2–4 quarters; share count grew 32% in 24 months; 1 cash raise in 24 months
ACTINOGEN MEDICAL LIMITED's ordinary share count grew 31.6% between September 2024 and September 2026, its latest share-count filing, to 3.87B shares. It raised capital once in that period, a Placement and SPP in February 2026 raising A$16.8M, the total disclosed proceeds. Options and rights on issue could convert into 453M new shares, representing an 11.7% overhang of the current share count, with none in the money at the current share price; the nearest expiry falls in May 2027. The company has 2 to 4 quarters of funding at the recent spend rate. No proposed securities issues are pending.
Quick answers · 5
When did ACW last raise capital?
The last capital raise in Actinogen Medical's filings is Placement and SPP of $16.8M announced 2 Feb 2026, one of 1 cash raises in 24 months.
How much placement capacity does ACW have left?
About 44% of the 15% placement capacity left, about 56% used in 12 months (estimate). Under ASX Listing Rule 7.1 a company may place up to 15% of its shares in 12 months without shareholder approval.
How much cash does ACW have?
In its quarterly cash report for the quarter ended 30 Sept 2026, Actinogen Medical reported $15.9M of cash and estimated 2.6 quarters of funding available at its current rate of spending. That is the company's own estimate.
When do ACW's options expire?
Unexercised options and rights equal 11.7% of Actinogen Medical's shares on issue; the nearest expiry is May 2027.
How much has ACW's share count grown?
Actinogen Medical has 3.87B shares on issue as at 28 Oct 2026, up 31.6% over 24 months according to its Appendix 2A filings.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 30 Sept 2026 | 2A · quoted issue | ACW : ORDINARY FULLY PAID | 3.87B | Appendix 2A |
| 23 Sept 2026 | 2A · quoted issue | ACW : ORDINARY FULLY PAID | 3.87B | Appendix 2A |
| 16 Sept 2026 | 3H · cancellation | ACW : ORDINARY FULLY PAID | 3.83B | Appendix 3H |
| 15 Sept 2026 | 2A · quoted issue | ACW : ORDINARY FULLY PAID | 3.85B | Appendix 2A |
| 11 Sept 2026 | 2A · quoted issue | ACW : ORDINARY FULLY PAID | 3.83B | Appendix 2A |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
1 cash raise in the last 24 months · 1 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 452.7M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| ACWOD | Options | Price-triggered, no exercise price stated | — | 31 May 2027 | 175.4M | Filing |
| ACWOC | Options | Price-triggered, no exercise price stated | — | 30 Sept 2027 | 277.2M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 9 Sept 2026 | Dr Geoffrey Brooke | Sell | 237k | 237k | — | $9k | 3Y notice |
| 28 Aug 2026 | Dr Geoffrey Brooke | Buy | 275k | — | — | $10k | 3Y notice |
| 28 Aug 2026 | Dr George Morstyn | Sell | 307k | 307k | — | $12k | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.